Cytokinetics Stock Forecast

Stock Price Forecast

According to 22 analysts polled by S&P Global, Cytokinetics stock has a consensus rating of "Buy" and an average price target of $104.7. The average 1-year stock price forecast is 34.04% higher than the current stock price, while the lowest is $69 (-11.66%) and the highest is $146 (+86.92%).

Price Target: $104.7 (+34.04%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$69	$104.7	$104	$146
Change	-11.66%	+34.04%	+33.15%	+86.92%

Analyst Ratings

The average analyst rating for Cytokinetics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	10	10	10	11	12	12
Buy	7	7	7	7	7	7
Hold	3	3	3	3	3	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	20	20	20	21	22	22

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Serge Belanger Needham	Needham	Buy Maintains $102	Buy	Maintains	$102	+30.59%	Jun 16, 2026
Tessa Romero J.P. Morgan	J.P. Morgan	Buy Maintains $97	Buy	Maintains	$97	+24.18%	Jun 5, 2026
Eric Joseph Citi	Citi	Buy Initiates $99	Buy	Initiates	$99	+26.74%	May 18, 2026
Maxwell Skor Morgan Stanley	Morgan Stanley	Buy Maintains $103	Buy	Maintains	$103	+31.87%	May 18, 2026
Joseph Pantginis H.C. Wainwright	H.C. Wainwright	Buy Reiterates $140	Buy	Reiterates	$140	+79.23%	May 11, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

109.27M

from 88.04M

24.12%

from 88.04M

Revenue Next Year

387.38M

from 109.27M

254.51%

from 109.27M

EPS This Year

-6.43

from -6.54

EPS Next Year

-4.75

from -6.43

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	70.43M	94.59M	7.53M	18.47M	88.04M	109.27M
Revenue Growth	26.15%	34.31%	-92.04%	145.34%	376.56%	24.12%
Gross Profit	-89.51M	-146.23M	-322.59M	-320.93M	-327.99M	100.97M
Gross Margin	-127.09%	-154.59%	-4,284.10%	-1,737.22%	-372.55%	92.40%
Operating Income	-186.31M	-324.20M	-496.21M	-536.25M	-612.26M	-752.42M
Net Income	-215.31M	-388.96M	-526.24M	-589.53M	-784.96M	-805.96M
EPS	-	-	-	-	-6.54	-6.43
Free Cash Flow	-179.83M	-127.01M	-260.37M	-241.29M	-379.62M	-661.35M
No. Analysts	-	-	-	-	-	19

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	182.4M
Avg	109.3M
Low	76.7M

Revenue Growth

Revenue Growth	2026	2027	2028
High	107.1%
Avg	24.1%
Low	-12.9%

EPS Forecast

EPS	2026	2027	2028
High	-4.80
Avg	-6.43
Low	-7.47

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-